 Jonathan Samet
Concepts (995)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Air Pollution | 73 | 2025 | 330 | 11.380 |
Why?
| | Smoking | 108 | 2018 | 1580 | 9.010 |
Why?
| | Air Pollutants | 73 | 2025 | 442 | 7.640 |
Why?
| | Tobacco Smoke Pollution | 52 | 2016 | 238 | 7.400 |
Why?
| | Environmental Exposure | 74 | 2025 | 588 | 7.340 |
Why?
| | Public Health | 54 | 2025 | 565 | 7.140 |
Why?
| | Neoplasms, Radiation-Induced | 33 | 2025 | 98 | 6.030 |
Why?
| | Smoking Prevention | 25 | 2021 | 170 | 5.090 |
Why?
| | Air Pollution, Indoor | 30 | 2024 | 183 | 4.470 |
Why?
| | Lung Neoplasms | 69 | 2026 | 2580 | 4.460 |
Why?
| | Epidemiology | 20 | 2020 | 33 | 4.210 |
Why?
| | Particulate Matter | 37 | 2025 | 342 | 4.150 |
Why?
| | Global Health | 22 | 2020 | 387 | 3.980 |
Why?
| | Smoking Cessation | 27 | 2021 | 435 | 3.620 |
Why?
| | Tobacco Industry | 19 | 2018 | 26 | 3.620 |
Why?
| | Tobacco Products | 17 | 2024 | 91 | 3.600 |
Why?
| | Occupational Exposure | 27 | 2025 | 347 | 3.450 |
Why?
| | Respiratory Tract Diseases | 29 | 2017 | 181 | 3.290 |
Why?
| | Radon | 28 | 2024 | 44 | 3.200 |
Why?
| | Mortality | 31 | 2024 | 364 | 3.050 |
Why?
| | Neoplasms | 35 | 2025 | 2804 | 3.000 |
Why?
| | Environmental Health | 14 | 2021 | 38 | 2.910 |
Why?
| | Occupational Diseases | 19 | 2024 | 161 | 2.760 |
Why?
| | Environmental Monitoring | 28 | 2024 | 374 | 2.520 |
Why?
| | Uranium | 18 | 2025 | 27 | 2.480 |
Why?
| | Humans | 445 | 2026 | 143560 | 2.480 |
Why?
| | Carcinogens | 9 | 2022 | 126 | 2.230 |
Why?
| | Electronic Nicotine Delivery Systems | 15 | 2024 | 108 | 2.200 |
Why?
| | United States | 124 | 2026 | 15553 | 2.070 |
Why?
| | Health Policy | 19 | 2020 | 393 | 2.010 |
Why?
| | Cardiovascular Diseases | 29 | 2017 | 2113 | 2.000 |
Why?
| | Ozone | 11 | 2024 | 135 | 1.880 |
Why?
| | Nuclear Weapons | 2 | 2025 | 7 | 1.820 |
Why?
| | Mining | 18 | 2025 | 34 | 1.810 |
Why?
| | Dronabinol | 3 | 2025 | 244 | 1.660 |
Why?
| | Epidemiologic Methods | 20 | 2012 | 94 | 1.610 |
Why?
| | Risk Assessment | 42 | 2020 | 3577 | 1.500 |
Why?
| | Epidemiologic Studies | 9 | 2024 | 68 | 1.490 |
Why?
| | Research | 13 | 2014 | 438 | 1.450 |
Why?
| | Politics | 7 | 2024 | 93 | 1.440 |
Why?
| | United States Environmental Protection Agency | 10 | 2020 | 28 | 1.420 |
Why?
| | Research Design | 15 | 2025 | 1123 | 1.370 |
Why?
| | History, 20th Century | 15 | 2025 | 327 | 1.370 |
Why?
| | Tobacco Use Disorder | 8 | 2015 | 237 | 1.310 |
Why?
| | Environmental Policy | 3 | 2020 | 6 | 1.310 |
Why?
| | Biomedical Research | 11 | 2020 | 699 | 1.220 |
Why?
| | Respiration Disorders | 7 | 2022 | 79 | 1.210 |
Why?
| | Forecasting | 13 | 2020 | 384 | 1.190 |
Why?
| | Risk Factors | 80 | 2025 | 10644 | 1.150 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 10 | 2025 | 1051 | 1.140 |
Why?
| | Developing Countries | 7 | 2014 | 308 | 1.130 |
Why?
| | Climate Change | 7 | 2023 | 197 | 1.110 |
Why?
| | Ventilation | 4 | 2024 | 46 | 1.100 |
Why?
| | Urban Health | 8 | 2014 | 95 | 1.070 |
Why?
| | Cost of Illness | 5 | 2018 | 319 | 1.060 |
Why?
| | Cannabis | 2 | 2025 | 520 | 1.040 |
Why?
| | Lung Diseases | 12 | 2018 | 787 | 1.030 |
Why?
| | Menthol | 5 | 2021 | 13 | 1.020 |
Why?
| | Nicotine | 18 | 2016 | 342 | 1.010 |
Why?
| | Causality | 8 | 2016 | 132 | 1.010 |
Why?
| | Inhalation Exposure | 7 | 2017 | 116 | 1.010 |
Why?
| | Nuclear Warfare | 4 | 2024 | 10 | 1.010 |
Why?
| | Models, Statistical | 17 | 2016 | 686 | 1.000 |
Why?
| | Cohort Studies | 38 | 2025 | 5891 | 0.970 |
Why?
| | International Agencies | 5 | 2022 | 32 | 0.940 |
Why?
| | Guidelines as Topic | 4 | 2020 | 270 | 0.940 |
Why?
| | Cotinine | 10 | 2014 | 78 | 0.930 |
Why?
| | Maternal Exposure | 5 | 2016 | 214 | 0.920 |
Why?
| | Health Status Disparities | 3 | 2019 | 307 | 0.910 |
Why?
| | History, 21st Century | 8 | 2025 | 220 | 0.890 |
Why?
| | Cell Phone | 3 | 2014 | 82 | 0.860 |
Why?
| | Particle Size | 19 | 2014 | 406 | 0.860 |
Why?
| | Tuberculosis | 2 | 2019 | 290 | 0.850 |
Why?
| | Asbestos | 5 | 2019 | 35 | 0.850 |
Why?
| | Government Regulation | 5 | 2017 | 37 | 0.850 |
Why?
| | Male | 154 | 2025 | 71500 | 0.850 |
Why?
| | Sleep Apnea Syndromes | 6 | 2016 | 90 | 0.840 |
Why?
| | Female | 154 | 2025 | 77251 | 0.840 |
Why?
| | Vaping | 6 | 2024 | 66 | 0.830 |
Why?
| | Environmental Pollutants | 3 | 2019 | 165 | 0.830 |
Why?
| | Population Health | 1 | 2024 | 45 | 0.820 |
Why?
| | Cause of Death | 12 | 2016 | 459 | 0.820 |
Why?
| | Adult | 105 | 2025 | 40013 | 0.810 |
Why?
| | Conservation of Natural Resources | 3 | 2020 | 131 | 0.800 |
Why?
| | Health Equity | 3 | 2021 | 117 | 0.790 |
Why?
| | Environmental Pollution | 2 | 2020 | 21 | 0.780 |
Why?
| | Public Policy | 11 | 2015 | 76 | 0.780 |
Why?
| | Aged | 89 | 2025 | 25322 | 0.770 |
Why?
| | Advisory Committees | 4 | 2020 | 215 | 0.770 |
Why?
| | Magnetic Resonance Imaging | 9 | 2026 | 3798 | 0.770 |
Why?
| | Urban Population | 12 | 2009 | 491 | 0.760 |
Why?
| | Vehicle Emissions | 7 | 2023 | 65 | 0.760 |
Why?
| | Child Health | 1 | 2024 | 155 | 0.750 |
Why?
| | Flavoring Agents | 3 | 2016 | 13 | 0.740 |
Why?
| | Incidence | 21 | 2024 | 2844 | 0.720 |
Why?
| | United States Food and Drug Administration | 5 | 2017 | 202 | 0.710 |
Why?
| | Asthma | 14 | 2014 | 1918 | 0.710 |
Why?
| | Middle Aged | 98 | 2025 | 35342 | 0.700 |
Why?
| | Brachial Plexus Neuropathies | 1 | 2021 | 19 | 0.690 |
Why?
| | Leadership | 6 | 2024 | 397 | 0.680 |
Why?
| | Brachial Plexus | 1 | 2021 | 34 | 0.680 |
Why?
| | Abnormalities, Radiation-Induced | 1 | 2020 | 1 | 0.680 |
Why?
| | Public Health Practice | 3 | 2019 | 67 | 0.670 |
Why?
| | Tobacco Smoking | 1 | 2020 | 25 | 0.670 |
Why?
| | Heart Diseases | 5 | 2013 | 340 | 0.670 |
Why?
| | Anniversaries and Special Events | 1 | 2020 | 17 | 0.670 |
Why?
| | New Mexico | 37 | 2002 | 103 | 0.660 |
Why?
| | Disease | 2 | 2019 | 99 | 0.660 |
Why?
| | Soft Tissue Neoplasms | 3 | 2026 | 122 | 0.650 |
Why?
| | Science | 2 | 2022 | 54 | 0.650 |
Why?
| | Social Control, Formal | 1 | 2020 | 11 | 0.640 |
Why?
| | Research Support as Topic | 6 | 2014 | 81 | 0.620 |
Why?
| | Smokers | 1 | 2020 | 146 | 0.620 |
Why?
| | Smoke | 4 | 2020 | 149 | 0.620 |
Why?
| | Health Care Costs | 3 | 2014 | 423 | 0.610 |
Why?
| | Risk | 22 | 2016 | 906 | 0.610 |
Why?
| | Radiation Exposure | 3 | 2025 | 61 | 0.610 |
Why?
| | Epidemiologists | 1 | 2019 | 5 | 0.600 |
Why?
| | Viruses | 1 | 2021 | 164 | 0.600 |
Why?
| | Filtration | 3 | 2017 | 69 | 0.600 |
Why?
| | Carcinogens, Environmental | 4 | 2015 | 14 | 0.600 |
Why?
| | Mexico | 15 | 2019 | 230 | 0.580 |
Why?
| | Morbidity | 7 | 2017 | 321 | 0.570 |
Why?
| | Minority Groups | 4 | 2017 | 279 | 0.560 |
Why?
| | International Cooperation | 10 | 2012 | 195 | 0.560 |
Why?
| | Indians, North American | 14 | 1995 | 661 | 0.560 |
Why?
| | Obesity, Abdominal | 1 | 2018 | 46 | 0.560 |
Why?
| | Professional Competence | 4 | 2019 | 96 | 0.550 |
Why?
| | Chernobyl Nuclear Accident | 1 | 2017 | 5 | 0.550 |
Why?
| | Proportional Hazards Models | 13 | 2025 | 1292 | 0.550 |
Why?
| | Publications | 2 | 2015 | 48 | 0.550 |
Why?
| | Smoke-Free Policy | 2 | 2018 | 13 | 0.540 |
Why?
| | Environmental Illness | 1 | 2017 | 3 | 0.540 |
Why?
| | Respiratory Tract Infections | 6 | 2024 | 389 | 0.540 |
Why?
| | Climate | 5 | 2013 | 89 | 0.530 |
Why?
| | Saliva | 6 | 2014 | 247 | 0.530 |
Why?
| | Japan | 6 | 2025 | 135 | 0.520 |
Why?
| | Cyclonic Storms | 1 | 2018 | 38 | 0.520 |
Why?
| | Radiology Information Systems | 3 | 2026 | 34 | 0.520 |
Why?
| | Age Factors | 20 | 2020 | 3328 | 0.520 |
Why?
| | Biomarkers, Tumor | 4 | 2025 | 1282 | 0.510 |
Why?
| | Air Pollutants, Radioactive | 5 | 2006 | 8 | 0.510 |
Why?
| | Harm Reduction | 4 | 2021 | 43 | 0.500 |
Why?
| | Chronic Disease | 4 | 2015 | 1824 | 0.500 |
Why?
| | Evidence-Based Practice | 5 | 2018 | 231 | 0.490 |
Why?
| | Pandemics | 3 | 2024 | 1668 | 0.490 |
Why?
| | Organizational Policy | 2 | 2014 | 77 | 0.490 |
Why?
| | Breast Neoplasms | 12 | 2009 | 2318 | 0.490 |
Why?
| | World Health Organization | 7 | 2016 | 103 | 0.490 |
Why?
| | Cities | 6 | 2024 | 140 | 0.490 |
Why?
| | Perinatal Death | 1 | 2016 | 26 | 0.490 |
Why?
| | Biological Transport, Active | 1 | 2016 | 70 | 0.490 |
Why?
| | Radiation Injuries | 1 | 2017 | 149 | 0.490 |
Why?
| | Nitrogen Dioxide | 7 | 2023 | 49 | 0.480 |
Why?
| | Prospective Studies | 22 | 2024 | 7899 | 0.480 |
Why?
| | Prevalence | 18 | 2020 | 2830 | 0.470 |
Why?
| | Hospitalization | 9 | 2009 | 2313 | 0.470 |
Why?
| | Stillbirth | 1 | 2016 | 75 | 0.470 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2016 | 36 | 0.470 |
Why?
| | Hazardous Substances | 4 | 2015 | 15 | 0.470 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 291 | 0.470 |
Why?
| | Obesity | 7 | 2018 | 3041 | 0.460 |
Why?
| | Cigarette Smoking | 4 | 2020 | 101 | 0.460 |
Why?
| | gamma-Glutamyltransferase | 1 | 2015 | 42 | 0.460 |
Why?
| | Population Surveillance | 10 | 2018 | 488 | 0.460 |
Why?
| | Tobacco Use | 1 | 2016 | 65 | 0.460 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 378 | 0.460 |
Why?
| | Bone Diseases | 1 | 2016 | 65 | 0.450 |
Why?
| | Coronavirus Infections | 1 | 2020 | 373 | 0.450 |
Why?
| | Organizations | 1 | 2015 | 26 | 0.450 |
Why?
| | Time Factors | 31 | 2019 | 7031 | 0.450 |
Why?
| | Nicotinic Agonists | 3 | 2013 | 136 | 0.440 |
Why?
| | Aged, 80 and over | 25 | 2025 | 8072 | 0.440 |
Why?
| | Dose-Response Relationship, Radiation | 5 | 2011 | 143 | 0.440 |
Why?
| | Body Mass Index | 7 | 2016 | 2429 | 0.440 |
Why?
| | Health Services Accessibility | 4 | 2017 | 1049 | 0.440 |
Why?
| | Republic of Korea | 6 | 2019 | 42 | 0.440 |
Why?
| | Epidemics | 1 | 2016 | 95 | 0.430 |
Why?
| | Health Facility Administration | 1 | 2014 | 7 | 0.430 |
Why?
| | Social Discrimination | 1 | 2014 | 12 | 0.430 |
Why?
| | Case-Control Studies | 21 | 2016 | 3625 | 0.420 |
Why?
| | Alkaloids | 1 | 2014 | 28 | 0.420 |
Why?
| | Linear Models | 9 | 2018 | 858 | 0.420 |
Why?
| | Odds Ratio | 15 | 2019 | 1060 | 0.410 |
Why?
| | Data Collection | 9 | 2019 | 655 | 0.410 |
Why?
| | Carbon Monoxide | 5 | 2022 | 83 | 0.410 |
Why?
| | Health Promotion | 6 | 2013 | 765 | 0.410 |
Why?
| | Behavior | 1 | 2014 | 92 | 0.410 |
Why?
| | Tuberculosis, Pulmonary | 2 | 2016 | 130 | 0.400 |
Why?
| | Lung | 12 | 2016 | 4101 | 0.400 |
Why?
| | Bronchi | 7 | 2000 | 267 | 0.400 |
Why?
| | Aerosols | 5 | 2021 | 180 | 0.400 |
Why?
| | Vanadium | 7 | 2009 | 10 | 0.390 |
Why?
| | Europe | 8 | 2024 | 410 | 0.390 |
Why?
| | Adolescent Behavior | 4 | 2016 | 541 | 0.390 |
Why?
| | Abortion, Spontaneous | 1 | 2014 | 117 | 0.390 |
Why?
| | Personnel Selection | 1 | 2014 | 88 | 0.390 |
Why?
| | Hot Temperature | 3 | 2014 | 408 | 0.380 |
Why?
| | Medicare | 7 | 2012 | 811 | 0.380 |
Why?
| | Sex Distribution | 8 | 2019 | 383 | 0.380 |
Why?
| | Workplace | 5 | 2011 | 270 | 0.380 |
Why?
| | Child | 35 | 2025 | 22725 | 0.380 |
Why?
| | Australia | 6 | 2024 | 290 | 0.380 |
Why?
| | Preventive Medicine | 1 | 2012 | 40 | 0.370 |
Why?
| | Regression Analysis | 10 | 2018 | 1013 | 0.370 |
Why?
| | Canada | 4 | 2024 | 433 | 0.370 |
Why?
| | Life Expectancy | 1 | 2013 | 73 | 0.370 |
Why?
| | Surveys and Questionnaires | 28 | 2024 | 6025 | 0.370 |
Why?
| | Korea | 6 | 2015 | 18 | 0.370 |
Why?
| | Lead | 6 | 2015 | 71 | 0.370 |
Why?
| | Exercise | 4 | 2021 | 2151 | 0.370 |
Why?
| | Child Welfare | 3 | 2004 | 230 | 0.370 |
Why?
| | Adolescent | 40 | 2025 | 22481 | 0.360 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2019 | 661 | 0.360 |
Why?
| | Research Report | 1 | 2012 | 81 | 0.360 |
Why?
| | Health Surveys | 9 | 2017 | 512 | 0.360 |
Why?
| | Meningioma | 2 | 2010 | 89 | 0.360 |
Why?
| | Diabetes Mellitus | 2 | 2019 | 1089 | 0.360 |
Why?
| | Respiratory Sounds | 4 | 2024 | 109 | 0.350 |
Why?
| | Adenocarcinoma | 4 | 2017 | 911 | 0.350 |
Why?
| | Genetic Predisposition to Disease | 5 | 2014 | 2417 | 0.350 |
Why?
| | Data Interpretation, Statistical | 5 | 2008 | 377 | 0.350 |
Why?
| | Miners | 2 | 2022 | 3 | 0.350 |
Why?
| | Coal | 3 | 2022 | 19 | 0.350 |
Why?
| | Drug and Narcotic Control | 1 | 2011 | 26 | 0.340 |
Why?
| | Leukocyte Count | 2 | 2005 | 317 | 0.340 |
Why?
| | Heat Stress Disorders | 2 | 2002 | 84 | 0.340 |
Why?
| | Copying Processes | 1 | 2010 | 1 | 0.340 |
Why?
| | Idiopathic Pulmonary Fibrosis | 2 | 2015 | 674 | 0.340 |
Why?
| | China | 8 | 2012 | 226 | 0.340 |
Why?
| | Americas | 3 | 2019 | 26 | 0.330 |
Why?
| | Veterans Disability Claims | 1 | 2010 | 4 | 0.330 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2016 | 2056 | 0.330 |
Why?
| | Women's Health | 2 | 2010 | 312 | 0.320 |
Why?
| | Wildfires | 2 | 2021 | 42 | 0.320 |
Why?
| | Seasons | 10 | 2021 | 556 | 0.320 |
Why?
| | Mass Screening | 1 | 2019 | 1334 | 0.320 |
Why?
| | Societies, Medical | 9 | 2026 | 873 | 0.320 |
Why?
| | Education, Public Health Professional | 2 | 2008 | 8 | 0.320 |
Why?
| | Congresses as Topic | 5 | 2018 | 226 | 0.320 |
Why?
| | Brazil | 4 | 2019 | 177 | 0.320 |
Why?
| | Career Choice | 2 | 2010 | 234 | 0.320 |
Why?
| | September 11 Terrorist Attacks | 2 | 2007 | 31 | 0.320 |
Why?
| | Air Microbiology | 3 | 2024 | 50 | 0.320 |
Why?
| | Rural Health | 2 | 2007 | 85 | 0.310 |
Why?
| | Young Adult | 21 | 2025 | 13972 | 0.310 |
Why?
| | Product Packaging | 3 | 2020 | 6 | 0.310 |
Why?
| | Health | 4 | 2018 | 83 | 0.310 |
Why?
| | Child, Preschool | 19 | 2024 | 11737 | 0.310 |
Why?
| | Carcinogenesis | 2 | 2022 | 232 | 0.300 |
Why?
| | Sex Factors | 14 | 2015 | 2092 | 0.300 |
Why?
| | Cystic Fibrosis | 3 | 2014 | 1142 | 0.300 |
Why?
| | Hair | 6 | 2014 | 89 | 0.300 |
Why?
| | Tobacco, Smokeless | 4 | 2016 | 13 | 0.300 |
Why?
| | Blood Glucose | 4 | 2022 | 2316 | 0.290 |
Why?
| | Deception | 1 | 2008 | 19 | 0.290 |
Why?
| | Housing | 7 | 2011 | 148 | 0.290 |
Why?
| | Expert Testimony | 2 | 2006 | 42 | 0.280 |
Why?
| | Glioma | 2 | 2010 | 425 | 0.280 |
Why?
| | Alcohol Drinking | 3 | 2005 | 852 | 0.280 |
Why?
| | Commerce | 4 | 2021 | 77 | 0.270 |
Why?
| | Effect Modifier, Epidemiologic | 1 | 2007 | 9 | 0.270 |
Why?
| | Information Dissemination | 2 | 2010 | 211 | 0.270 |
Why?
| | Biomarkers | 10 | 2017 | 4241 | 0.270 |
Why?
| | Air Pollutants, Occupational | 4 | 2008 | 41 | 0.270 |
Why?
| | Spirometry | 4 | 2016 | 263 | 0.270 |
Why?
| | Evidence-Based Medicine | 6 | 2014 | 724 | 0.270 |
Why?
| | Musculoskeletal Diseases | 2 | 2025 | 87 | 0.260 |
Why?
| | Environment, Controlled | 2 | 2006 | 23 | 0.260 |
Why?
| | Registries | 8 | 2022 | 2238 | 0.260 |
Why?
| | Construction Materials | 1 | 2007 | 18 | 0.260 |
Why?
| | Professional Role | 3 | 2019 | 167 | 0.250 |
Why?
| | Foundations | 3 | 2018 | 28 | 0.250 |
Why?
| | Education | 2 | 2018 | 107 | 0.250 |
Why?
| | Bias | 6 | 2018 | 208 | 0.250 |
Why?
| | Ontario | 3 | 2019 | 96 | 0.250 |
Why?
| | Marketing | 4 | 2021 | 24 | 0.250 |
Why?
| | Growth Disorders | 1 | 2007 | 87 | 0.250 |
Why?
| | Muscle Neoplasms | 1 | 2026 | 9 | 0.240 |
Why?
| | Social Environment | 2 | 2019 | 297 | 0.240 |
Why?
| | Tomography, X-Ray Computed | 2 | 2007 | 2779 | 0.240 |
Why?
| | Los Angeles | 4 | 2024 | 75 | 0.240 |
Why?
| | Sarcoma, Small Cell | 1 | 2025 | 2 | 0.240 |
Why?
| | Academies and Institutes | 4 | 2022 | 61 | 0.240 |
Why?
| | Publishing | 2 | 2014 | 111 | 0.240 |
Why?
| | Radon Daughters | 5 | 2022 | 5 | 0.240 |
Why?
| | RNA-Binding Protein EWS | 1 | 2025 | 28 | 0.240 |
Why?
| | RNA-Binding Protein FUS | 1 | 2025 | 15 | 0.240 |
Why?
| | Thoracic Neoplasms | 1 | 2026 | 39 | 0.230 |
Why?
| | National Institutes of Health (U.S.) | 3 | 2018 | 135 | 0.230 |
Why?
| | Neurofibroma, Plexiform | 1 | 2025 | 12 | 0.230 |
Why?
| | Metals | 4 | 1999 | 142 | 0.230 |
Why?
| | Teaching | 1 | 2008 | 233 | 0.230 |
Why?
| | Respiratory System | 2 | 2021 | 156 | 0.230 |
Why?
| | NFATC Transcription Factors | 1 | 2025 | 94 | 0.230 |
Why?
| | Retrospective Studies | 13 | 2025 | 16741 | 0.230 |
Why?
| | Anemia | 1 | 2007 | 177 | 0.230 |
Why?
| | Disease Susceptibility | 3 | 2018 | 354 | 0.230 |
Why?
| | Soft Tissue Infections | 1 | 2025 | 41 | 0.230 |
Why?
| | Bayes Theorem | 5 | 2006 | 426 | 0.220 |
Why?
| | Neurofibromatosis 1 | 1 | 2025 | 55 | 0.220 |
Why?
| | Sacroiliac Joint | 1 | 2025 | 35 | 0.220 |
Why?
| | Myocardial Infarction | 1 | 2012 | 1072 | 0.220 |
Why?
| | Program Evaluation | 3 | 2020 | 937 | 0.220 |
Why?
| | Epidemiologic Research Design | 3 | 2004 | 28 | 0.220 |
Why?
| | Infant | 16 | 2016 | 9981 | 0.220 |
Why?
| | Radiography, Thoracic | 1 | 2006 | 180 | 0.220 |
Why?
| | Diagnosis, Differential | 4 | 2026 | 1504 | 0.220 |
Why?
| | Laryngeal Neoplasms | 2 | 2004 | 34 | 0.220 |
Why?
| | Age Distribution | 5 | 2013 | 398 | 0.220 |
Why?
| | Airports | 1 | 2024 | 3 | 0.220 |
Why?
| | Lactoferrin | 3 | 1999 | 38 | 0.210 |
Why?
| | Mutagens | 1 | 2004 | 26 | 0.210 |
Why?
| | Radiation, Ionizing | 1 | 2024 | 83 | 0.210 |
Why?
| | Health Services Research | 2 | 2014 | 402 | 0.210 |
Why?
| | Infant, Newborn | 15 | 2016 | 6366 | 0.210 |
Why?
| | Health Personnel | 3 | 2022 | 736 | 0.210 |
Why?
| | Hepatitis B | 1 | 2004 | 71 | 0.210 |
Why?
| | Cleft Palate | 2 | 2015 | 81 | 0.210 |
Why?
| | Rhinovirus | 1 | 2004 | 58 | 0.210 |
Why?
| | Mortality, Premature | 2 | 2024 | 14 | 0.210 |
Why?
| | National Health Programs | 2 | 2019 | 21 | 0.210 |
Why?
| | Epidemiological Monitoring | 7 | 2008 | 71 | 0.210 |
Why?
| | Cross-Sectional Studies | 18 | 2024 | 5743 | 0.210 |
Why?
| | Glycerol | 1 | 2024 | 90 | 0.200 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2025 | 213 | 0.200 |
Why?
| | Time | 2 | 2003 | 87 | 0.200 |
Why?
| | Vulnerable Populations | 2 | 2015 | 175 | 0.200 |
Why?
| | Environment Design | 1 | 2003 | 27 | 0.200 |
Why?
| | Liability, Legal | 2 | 2006 | 43 | 0.200 |
Why?
| | Medical Marijuana | 1 | 2025 | 124 | 0.200 |
Why?
| | Osteomyelitis | 1 | 2025 | 143 | 0.200 |
Why?
| | Hypertension | 5 | 2012 | 1260 | 0.200 |
Why?
| | Pregnancy | 11 | 2016 | 7153 | 0.200 |
Why?
| | Logistic Models | 10 | 2016 | 2107 | 0.200 |
Why?
| | Brain Neoplasms | 2 | 2010 | 1300 | 0.200 |
Why?
| | Germ-Line Mutation | 1 | 2004 | 173 | 0.200 |
Why?
| | Dust | 4 | 2007 | 99 | 0.200 |
Why?
| | Diabetes Complications | 1 | 2005 | 222 | 0.200 |
Why?
| | Bone Neoplasms | 1 | 2025 | 249 | 0.200 |
Why?
| | Fasting | 1 | 2005 | 284 | 0.190 |
Why?
| | Sensitivity and Specificity | 4 | 2016 | 1984 | 0.190 |
Why?
| | Travel | 1 | 2004 | 145 | 0.190 |
Why?
| | Weather | 5 | 2009 | 42 | 0.190 |
Why?
| | Disinfection | 1 | 2024 | 130 | 0.190 |
Why?
| | Databases as Topic | 4 | 2008 | 69 | 0.190 |
Why?
| | Reproducibility of Results | 6 | 2025 | 3380 | 0.190 |
Why?
| | Polonium | 3 | 1991 | 3 | 0.190 |
Why?
| | Electromagnetic Fields | 2 | 2014 | 38 | 0.180 |
Why?
| | Financial Support | 2 | 2016 | 17 | 0.180 |
Why?
| | California | 5 | 2025 | 467 | 0.180 |
Why?
| | Healthcare Disparities | 2 | 2020 | 691 | 0.180 |
Why?
| | Risk Management | 3 | 2008 | 91 | 0.180 |
Why?
| | Adrenal Cortex Hormones | 1 | 2005 | 505 | 0.180 |
Why?
| | Pfiesteria piscicida | 1 | 2001 | 1 | 0.180 |
Why?
| | Engineering | 1 | 2022 | 30 | 0.180 |
Why?
| | Shoulder Joint | 1 | 2024 | 177 | 0.180 |
Why?
| | Nickel | 4 | 2009 | 61 | 0.180 |
Why?
| | Protozoan Infections | 1 | 2001 | 11 | 0.180 |
Why?
| | Recurrence | 2 | 2019 | 1114 | 0.180 |
Why?
| | Policy Making | 4 | 2012 | 81 | 0.180 |
Why?
| | Analgesics | 1 | 2023 | 235 | 0.180 |
Why?
| | Lumbosacral Plexus | 1 | 2021 | 9 | 0.180 |
Why?
| | Estrogen Replacement Therapy | 1 | 2002 | 143 | 0.170 |
Why?
| | Baltimore | 5 | 2014 | 70 | 0.170 |
Why?
| | Gases | 2 | 2007 | 52 | 0.170 |
Why?
| | Pulmonary Fibrosis | 3 | 2000 | 392 | 0.170 |
Why?
| | Plants, Toxic | 2 | 1998 | 19 | 0.170 |
Why?
| | Conflict of Interest | 1 | 2001 | 48 | 0.170 |
Why?
| | Maximum Allowable Concentration | 2 | 2015 | 16 | 0.170 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2004 | 365 | 0.170 |
Why?
| | Hyperglycemia | 1 | 2005 | 365 | 0.170 |
Why?
| | SEER Program | 2 | 2021 | 220 | 0.170 |
Why?
| | Bismuth | 2 | 1991 | 3 | 0.170 |
Why?
| | Receptors, Cell Surface | 2 | 2001 | 379 | 0.170 |
Why?
| | Reproduction | 2 | 2001 | 206 | 0.170 |
Why?
| | Residence Characteristics | 4 | 2018 | 376 | 0.170 |
Why?
| | Extremities | 3 | 2024 | 141 | 0.160 |
Why?
| | Patient Admission | 3 | 2012 | 203 | 0.160 |
Why?
| | Medicine | 1 | 2022 | 125 | 0.160 |
Why?
| | Social Determinants of Health | 1 | 2024 | 293 | 0.160 |
Why?
| | Confidentiality | 2 | 2019 | 74 | 0.160 |
Why?
| | Poisson Distribution | 3 | 2012 | 76 | 0.160 |
Why?
| | Algorithms | 6 | 2026 | 1813 | 0.160 |
Why?
| | Health Priorities | 4 | 2010 | 43 | 0.160 |
Why?
| | Clinical Medicine | 1 | 2000 | 25 | 0.160 |
Why?
| | Follow-Up Studies | 10 | 2020 | 5308 | 0.150 |
Why?
| | Arachidonic Acid | 3 | 2001 | 107 | 0.150 |
Why?
| | Competency-Based Education | 1 | 2020 | 83 | 0.150 |
Why?
| | Panama | 1 | 2019 | 14 | 0.150 |
Why?
| | Minnesota | 3 | 2009 | 172 | 0.150 |
Why?
| | Anti-Inflammatory Agents | 1 | 2003 | 482 | 0.150 |
Why?
| | Talc | 1 | 2019 | 9 | 0.150 |
Why?
| | Carbon | 5 | 2009 | 205 | 0.150 |
Why?
| | Petroleum Pollution | 1 | 2019 | 10 | 0.150 |
Why?
| | Biodiversity | 1 | 2023 | 421 | 0.150 |
Why?
| | Public Health Surveillance | 1 | 2020 | 83 | 0.150 |
Why?
| | Models, Theoretical | 5 | 2014 | 586 | 0.150 |
Why?
| | Animals | 18 | 2020 | 38010 | 0.150 |
Why?
| | Mast Cells | 2 | 2001 | 151 | 0.150 |
Why?
| | Policy | 2 | 2021 | 150 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2023 | 365 | 0.150 |
Why?
| | Licensure | 1 | 2019 | 15 | 0.150 |
Why?
| | Peripheral Nerve Injuries | 1 | 2019 | 38 | 0.150 |
Why?
| | Authorship | 1 | 1999 | 46 | 0.150 |
Why?
| | Arsenic | 1 | 1999 | 64 | 0.150 |
Why?
| | Catholicism | 1 | 2018 | 9 | 0.150 |
Why?
| | Mental Health | 1 | 2025 | 770 | 0.140 |
Why?
| | Molecular Epidemiology | 2 | 2009 | 72 | 0.140 |
Why?
| | Disasters | 3 | 2018 | 100 | 0.140 |
Why?
| | HIV Infections | 5 | 2016 | 3013 | 0.140 |
Why?
| | Weight Gain | 1 | 2002 | 550 | 0.140 |
Why?
| | Prognosis | 8 | 2026 | 4152 | 0.140 |
Why?
| | Social Responsibility | 1 | 2018 | 52 | 0.140 |
Why?
| | Human Migration | 1 | 2018 | 25 | 0.140 |
Why?
| | Greenhouse Gases | 1 | 2018 | 8 | 0.140 |
Why?
| | Transferrin | 1 | 1998 | 50 | 0.140 |
Why?
| | Liver Neoplasms | 1 | 2004 | 758 | 0.140 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 1999 | 168 | 0.140 |
Why?
| | Veterans | 1 | 2010 | 1544 | 0.140 |
Why?
| | Glycine | 1 | 2019 | 187 | 0.140 |
Why?
| | Emergency Service, Hospital | 2 | 2009 | 2270 | 0.140 |
Why?
| | Writing | 1 | 1999 | 99 | 0.140 |
Why?
| | Radiobiology | 1 | 2017 | 6 | 0.140 |
Why?
| | Poverty | 3 | 2023 | 528 | 0.140 |
Why?
| | Frail Elderly | 1 | 1999 | 132 | 0.140 |
Why?
| | Models, Biological | 4 | 2015 | 1831 | 0.140 |
Why?
| | Restaurants | 3 | 2012 | 22 | 0.140 |
Why?
| | Health Communication | 1 | 2018 | 49 | 0.140 |
Why?
| | Cross-Over Studies | 4 | 2022 | 583 | 0.140 |
Why?
| | Sleep | 3 | 2018 | 889 | 0.130 |
Why?
| | Ferritins | 4 | 1998 | 66 | 0.130 |
Why?
| | Industry | 2 | 2010 | 41 | 0.130 |
Why?
| | Antioxidants | 1 | 2001 | 594 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 280 | 0.130 |
Why?
| | Cross-Cultural Comparison | 3 | 1994 | 85 | 0.130 |
Why?
| | Heating | 3 | 2007 | 18 | 0.130 |
Why?
| | Pulmonary Medicine | 2 | 2017 | 83 | 0.130 |
Why?
| | Air | 2 | 2010 | 44 | 0.130 |
Why?
| | Bronchitis, Chronic | 1 | 2017 | 24 | 0.130 |
Why?
| | Public Health Administration | 1 | 2018 | 74 | 0.130 |
Why?
| | Economics | 1 | 2017 | 11 | 0.130 |
Why?
| | Imaging, Three-Dimensional | 1 | 2021 | 569 | 0.130 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2022 | 2575 | 0.130 |
Why?
| | Publication Bias | 2 | 2008 | 17 | 0.130 |
Why?
| | Periodicals as Topic | 1 | 1999 | 202 | 0.130 |
Why?
| | Social Class | 3 | 2017 | 273 | 0.130 |
Why?
| | Universities | 2 | 2016 | 455 | 0.130 |
Why?
| | Occupational Health | 1 | 1999 | 206 | 0.130 |
Why?
| | Environment | 2 | 2012 | 343 | 0.130 |
Why?
| | Radiation Dosage | 4 | 2007 | 195 | 0.130 |
Why?
| | Dioxins | 1 | 1996 | 7 | 0.120 |
Why?
| | Stem Cell Factor | 1 | 1996 | 17 | 0.120 |
Why?
| | Ferric Compounds | 1 | 1997 | 55 | 0.120 |
Why?
| | Iran | 1 | 2016 | 45 | 0.120 |
Why?
| | North America | 4 | 2021 | 308 | 0.120 |
Why?
| | Mental Disorders | 1 | 2025 | 1151 | 0.120 |
Why?
| | Zinc | 1 | 1999 | 300 | 0.120 |
Why?
| | Peer Influence | 1 | 2016 | 14 | 0.120 |
Why?
| | Product Labeling | 1 | 2016 | 11 | 0.120 |
Why?
| | Capacity Building | 1 | 2016 | 59 | 0.120 |
Why?
| | Eating | 1 | 2018 | 397 | 0.120 |
Why?
| | Polycyclic Aromatic Hydrocarbons | 2 | 2007 | 28 | 0.120 |
Why?
| | Xenobiotics | 1 | 1995 | 33 | 0.120 |
Why?
| | Emigrants and Immigrants | 1 | 2018 | 154 | 0.120 |
Why?
| | Coinfection | 1 | 2016 | 133 | 0.110 |
Why?
| | Socioeconomic Factors | 5 | 2016 | 1324 | 0.110 |
Why?
| | Polychlorinated Dibenzodioxins | 2 | 2010 | 8 | 0.110 |
Why?
| | Air Pollution, Radioactive | 1 | 1994 | 2 | 0.110 |
Why?
| | Asia | 4 | 2024 | 67 | 0.110 |
Why?
| | Internationality | 1 | 2016 | 158 | 0.110 |
Why?
| | Schools, Medical | 1 | 2016 | 158 | 0.110 |
Why?
| | Cooking | 2 | 2023 | 67 | 0.110 |
Why?
| | Primary Health Care | 1 | 2005 | 1779 | 0.110 |
Why?
| | Insurance, Health | 2 | 2009 | 299 | 0.110 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2014 | 320 | 0.110 |
Why?
| | Motivation | 1 | 2020 | 609 | 0.110 |
Why?
| | Radiation Effects | 2 | 2004 | 7 | 0.110 |
Why?
| | Oxidants | 1 | 1994 | 104 | 0.110 |
Why?
| | Latin America | 1 | 2014 | 89 | 0.110 |
Why?
| | PubMed | 1 | 2014 | 14 | 0.100 |
Why?
| | Review Literature as Topic | 1 | 2014 | 49 | 0.100 |
Why?
| | Silicosis | 1 | 1994 | 28 | 0.100 |
Why?
| | Cleft Lip | 1 | 2014 | 65 | 0.100 |
Why?
| | Mastectomy, Segmental | 1 | 1994 | 101 | 0.100 |
Why?
| | Pelvic Bones | 1 | 2016 | 132 | 0.100 |
Why?
| | Ganglionic Stimulants | 2 | 2015 | 15 | 0.100 |
Why?
| | Mucus | 1 | 1994 | 79 | 0.100 |
Why?
| | Temperature | 5 | 2005 | 676 | 0.100 |
Why?
| | Drug Synergism | 1 | 2014 | 370 | 0.100 |
Why?
| | Breast | 1 | 1994 | 158 | 0.100 |
Why?
| | Health Plan Implementation | 1 | 2014 | 143 | 0.100 |
Why?
| | Community Networks | 1 | 2013 | 57 | 0.100 |
Why?
| | Analysis of Variance | 4 | 2009 | 1314 | 0.100 |
Why?
| | Benzene | 2 | 2023 | 18 | 0.100 |
Why?
| | Taxes | 2 | 2010 | 15 | 0.100 |
Why?
| | History, 19th Century | 1 | 2013 | 61 | 0.100 |
Why?
| | Bone and Bones | 1 | 2016 | 321 | 0.100 |
Why?
| | Greenhouse Effect | 3 | 2001 | 10 | 0.100 |
Why?
| | American Cancer Society | 2 | 2009 | 5 | 0.100 |
Why?
| | Administration, Inhalation | 2 | 2005 | 597 | 0.100 |
Why?
| | Zonula Occludens-1 Protein | 1 | 2012 | 17 | 0.100 |
Why?
| | Names | 1 | 2012 | 14 | 0.100 |
Why?
| | Iron | 4 | 1999 | 345 | 0.100 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2024 | 188 | 0.100 |
Why?
| | Snoring | 2 | 2010 | 18 | 0.090 |
Why?
| | Local Government | 1 | 2012 | 26 | 0.090 |
Why?
| | Calpain | 1 | 2012 | 60 | 0.090 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 1133 | 0.090 |
Why?
| | Sodium, Dietary | 1 | 2012 | 38 | 0.090 |
Why?
| | Inflammation | 4 | 2023 | 2881 | 0.090 |
Why?
| | Program Development | 1 | 2014 | 371 | 0.090 |
Why?
| | Allergens | 2 | 2014 | 408 | 0.090 |
Why?
| | United Kingdom | 2 | 2006 | 334 | 0.090 |
Why?
| | Nonlinear Dynamics | 2 | 2003 | 94 | 0.090 |
Why?
| | TRPM Cation Channels | 1 | 2012 | 75 | 0.090 |
Why?
| | Feeding Behavior | 1 | 1998 | 688 | 0.090 |
Why?
| | Sampling Studies | 2 | 2006 | 103 | 0.090 |
Why?
| | Diet, Carbohydrate-Restricted | 2 | 2022 | 37 | 0.090 |
Why?
| | Public Facilities | 2 | 2008 | 5 | 0.090 |
Why?
| | Maryland | 2 | 2008 | 62 | 0.090 |
Why?
| | Eosinophils | 1 | 2014 | 325 | 0.090 |
Why?
| | Pennsylvania | 5 | 2006 | 135 | 0.090 |
Why?
| | Body Temperature | 2 | 2002 | 224 | 0.090 |
Why?
| | Ethiopia | 2 | 2021 | 40 | 0.090 |
Why?
| | Sick Building Syndrome | 1 | 2011 | 4 | 0.090 |
Why?
| | Students, Medical | 1 | 2016 | 372 | 0.090 |
Why?
| | Communicable Diseases | 2 | 2011 | 165 | 0.080 |
Why?
| | Crime | 1 | 2011 | 60 | 0.080 |
Why?
| | Printing | 1 | 2010 | 5 | 0.080 |
Why?
| | Manufactured Materials | 1 | 2010 | 8 | 0.080 |
Why?
| | Cell Line, Transformed | 3 | 1999 | 146 | 0.080 |
Why?
| | Self Report | 4 | 2017 | 877 | 0.080 |
Why?
| | Pregnancy, Ectopic | 1 | 1991 | 54 | 0.080 |
Why?
| | Health Education | 4 | 2014 | 363 | 0.080 |
Why?
| | Defoliants, Chemical | 1 | 2010 | 1 | 0.080 |
Why?
| | Agent Orange | 1 | 2010 | 2 | 0.080 |
Why?
| | 2,4,5-Trichlorophenoxyacetic Acid | 1 | 2010 | 2 | 0.080 |
Why?
| | Maternal Welfare | 1 | 2010 | 20 | 0.080 |
Why?
| | 2,4-Dichlorophenoxyacetic Acid | 1 | 2010 | 13 | 0.080 |
Why?
| | Aging | 2 | 2002 | 1946 | 0.080 |
Why?
| | Waist Circumference | 1 | 2010 | 137 | 0.080 |
Why?
| | Lung Diseases, Obstructive | 2 | 1988 | 43 | 0.080 |
Why?
| | Prostatic Neoplasms | 3 | 1996 | 1058 | 0.080 |
Why?
| | New York City | 2 | 2007 | 90 | 0.080 |
Why?
| | Suicide | 1 | 2017 | 677 | 0.080 |
Why?
| | Water Pollution | 2 | 2018 | 9 | 0.080 |
Why?
| | Curriculum | 2 | 2008 | 1047 | 0.080 |
Why?
| | Developed Countries | 1 | 2010 | 38 | 0.080 |
Why?
| | Disclosure | 1 | 2010 | 86 | 0.080 |
Why?
| | Legislation as Topic | 1 | 2009 | 5 | 0.080 |
Why?
| | Carcinoma | 2 | 2007 | 230 | 0.080 |
Why?
| | Legislation, Medical | 1 | 2009 | 11 | 0.080 |
Why?
| | Radioactive Pollutants | 1 | 1989 | 1 | 0.080 |
Why?
| | Medical Record Linkage | 2 | 2013 | 68 | 0.080 |
Why?
| | Monte Carlo Method | 1 | 2009 | 154 | 0.080 |
Why?
| | Food Contamination, Radioactive | 1 | 1989 | 1 | 0.080 |
Why?
| | Radioisotopes | 1 | 1989 | 33 | 0.070 |
Why?
| | Birth Weight | 1 | 2012 | 520 | 0.070 |
Why?
| | Cooperative Behavior | 2 | 2018 | 458 | 0.070 |
Why?
| | Survival Rate | 5 | 2009 | 2003 | 0.070 |
Why?
| | Models, Econometric | 1 | 2009 | 36 | 0.070 |
Why?
| | Costs and Cost Analysis | 1 | 2010 | 220 | 0.070 |
Why?
| | Gallbladder Diseases | 1 | 1988 | 11 | 0.070 |
Why?
| | Phospholipases A | 2 | 2001 | 101 | 0.070 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2009 | 134 | 0.070 |
Why?
| | New York | 2 | 2010 | 131 | 0.070 |
Why?
| | ROC Curve | 1 | 2010 | 603 | 0.070 |
Why?
| | Nicotinic Antagonists | 1 | 2008 | 36 | 0.070 |
Why?
| | Epithelial Cells | 6 | 2000 | 1125 | 0.070 |
Why?
| | Decision Making | 3 | 2010 | 962 | 0.070 |
Why?
| | Interdisciplinary Communication | 2 | 2011 | 198 | 0.070 |
Why?
| | Students, Public Health | 1 | 2008 | 1 | 0.070 |
Why?
| | Computer Simulation | 2 | 2009 | 1028 | 0.070 |
Why?
| | Nutrition Surveys | 2 | 2012 | 282 | 0.070 |
Why?
| | Dyspnea | 3 | 2024 | 259 | 0.070 |
Why?
| | DNA Damage | 2 | 2004 | 446 | 0.070 |
Why?
| | Cells, Cultured | 6 | 2012 | 4182 | 0.070 |
Why?
| | Epidemiologic Factors | 2 | 2002 | 10 | 0.070 |
Why?
| | Signal Transduction | 3 | 2003 | 5214 | 0.070 |
Why?
| | Pregnancy Outcome | 1 | 1991 | 464 | 0.070 |
Why?
| | Bone Marrow Cells | 2 | 2001 | 319 | 0.070 |
Why?
| | Bronchial Hyperreactivity | 1 | 2008 | 102 | 0.070 |
Why?
| | Spectroscopy, Fourier Transform Infrared | 1 | 2007 | 88 | 0.070 |
Why?
| | Financing, Government | 2 | 2004 | 49 | 0.070 |
Why?
| | Coal Ash | 4 | 2000 | 8 | 0.070 |
Why?
| | Cardiovascular System | 1 | 2009 | 137 | 0.070 |
Why?
| | Menopause | 2 | 2002 | 317 | 0.070 |
Why?
| | Rescue Work | 1 | 2007 | 11 | 0.070 |
Why?
| | Predictive Value of Tests | 3 | 2010 | 2086 | 0.070 |
Why?
| | Polysomnography | 5 | 2009 | 242 | 0.070 |
Why?
| | Overweight | 2 | 2016 | 598 | 0.070 |
Why?
| | Automobile Driving | 1 | 2009 | 153 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2014 | 954 | 0.070 |
Why?
| | Insurance Coverage | 1 | 2009 | 240 | 0.060 |
Why?
| | Tars | 1 | 2006 | 5 | 0.060 |
Why?
| | Schools, Public Health | 1 | 2006 | 4 | 0.060 |
Why?
| | Genome-Wide Association Study | 2 | 2014 | 1452 | 0.060 |
Why?
| | Poland | 1 | 2006 | 35 | 0.060 |
Why?
| | Chromatography, Gas | 1 | 2006 | 32 | 0.060 |
Why?
| | Cost-Benefit Analysis | 1 | 2009 | 621 | 0.060 |
Why?
| | Forced Expiratory Volume | 3 | 2016 | 485 | 0.060 |
Why?
| | Multivariate Analysis | 5 | 2009 | 1510 | 0.060 |
Why?
| | Energy Intake | 2 | 2001 | 513 | 0.060 |
Why?
| | Geography | 2 | 2008 | 202 | 0.060 |
Why?
| | Quality Improvement | 1 | 2015 | 1263 | 0.060 |
Why?
| | Survival Analysis | 2 | 2004 | 1332 | 0.060 |
Why?
| | NF-kappa B | 3 | 2001 | 685 | 0.060 |
Why?
| | Biomass | 1 | 2007 | 115 | 0.060 |
Why?
| | Sulfur Dioxide | 4 | 2001 | 13 | 0.060 |
Why?
| | Practice Guidelines as Topic | 3 | 2017 | 1557 | 0.060 |
Why?
| | Cattle | 1 | 1989 | 990 | 0.060 |
Why?
| | Single Person | 1 | 1986 | 7 | 0.060 |
Why?
| | Statistics, Nonparametric | 2 | 2009 | 434 | 0.060 |
Why?
| | Gift Giving | 1 | 2006 | 9 | 0.060 |
Why?
| | Sleep Stages | 1 | 2006 | 76 | 0.060 |
Why?
| | Fires | 1 | 2007 | 89 | 0.060 |
Why?
| | ErbB Receptors | 1 | 2009 | 617 | 0.060 |
Why?
| | Cough | 1 | 2007 | 133 | 0.060 |
Why?
| | Students | 3 | 2016 | 655 | 0.060 |
Why?
| | Computer-Assisted Instruction | 1 | 2006 | 69 | 0.060 |
Why?
| | Health Status | 2 | 2020 | 824 | 0.060 |
Why?
| | Models, Educational | 1 | 2006 | 95 | 0.060 |
Why?
| | Thinness | 1 | 2006 | 98 | 0.060 |
Why?
| | Biological Specimen Banks | 1 | 2006 | 99 | 0.060 |
Why?
| | Meta-Analysis as Topic | 1 | 2006 | 169 | 0.060 |
Why?
| | Interinstitutional Relations | 1 | 2006 | 50 | 0.060 |
Why?
| | Bioterrorism | 1 | 2006 | 31 | 0.060 |
Why?
| | Consensus | 1 | 2008 | 550 | 0.060 |
Why?
| | Peripheral Arterial Disease | 1 | 2012 | 498 | 0.060 |
Why?
| | Education, Distance | 1 | 2006 | 55 | 0.060 |
Why?
| | Endothelium, Vascular | 1 | 2012 | 962 | 0.060 |
Why?
| | Behavior, Addictive | 1 | 2006 | 89 | 0.060 |
Why?
| | United States Department of Veterans Affairs | 1 | 2010 | 734 | 0.060 |
Why?
| | Rats | 4 | 1998 | 5610 | 0.060 |
Why?
| | Communicable Disease Control | 1 | 2006 | 86 | 0.060 |
Why?
| | Interviews as Topic | 4 | 2010 | 868 | 0.060 |
Why?
| | Goals | 1 | 2007 | 182 | 0.060 |
Why?
| | Hepatitis B Surface Antigens | 1 | 2004 | 21 | 0.060 |
Why?
| | Deferoxamine | 3 | 1999 | 26 | 0.060 |
Why?
| | Mexican Americans | 2 | 2018 | 114 | 0.050 |
Why?
| | Financing, Organized | 1 | 2004 | 35 | 0.050 |
Why?
| | Uruguay | 1 | 2004 | 2 | 0.050 |
Why?
| | Paraguay | 1 | 2004 | 3 | 0.050 |
Why?
| | Disaster Planning | 1 | 2006 | 96 | 0.050 |
Why?
| | Immunohistochemistry | 2 | 1999 | 1736 | 0.050 |
Why?
| | Stroke | 1 | 2013 | 1213 | 0.050 |
Why?
| | Costa Rica | 1 | 2004 | 18 | 0.050 |
Why?
| | Longitudinal Studies | 3 | 2016 | 3006 | 0.050 |
Why?
| | Argentina | 1 | 2004 | 29 | 0.050 |
Why?
| | Spermatogonia | 1 | 2004 | 15 | 0.050 |
Why?
| | Chile | 1 | 2004 | 25 | 0.050 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2015 | 647 | 0.050 |
Why?
| | Observer Variation | 1 | 2025 | 361 | 0.050 |
Why?
| | Diet Surveys | 1 | 1984 | 93 | 0.050 |
Why?
| | Tandem Repeat Sequences | 1 | 2004 | 21 | 0.050 |
Why?
| | No-Observed-Adverse-Effect Level | 1 | 2004 | 7 | 0.050 |
Why?
| | Glomerular Filtration Rate | 1 | 2008 | 775 | 0.050 |
Why?
| | Peru | 1 | 2004 | 61 | 0.050 |
Why?
| | Electroencephalography | 1 | 2007 | 531 | 0.050 |
Why?
| | Uganda | 1 | 2024 | 89 | 0.050 |
Why?
| | Picornaviridae | 1 | 2004 | 20 | 0.050 |
Why?
| | Bronchodilator Agents | 1 | 2005 | 196 | 0.050 |
Why?
| | Diet | 4 | 2003 | 1290 | 0.050 |
Why?
| | Mentors | 2 | 2003 | 215 | 0.050 |
Why?
| | Aircraft | 1 | 2004 | 23 | 0.050 |
Why?
| | Shoulder Pain | 1 | 2024 | 32 | 0.050 |
Why?
| | Nose Diseases | 1 | 2004 | 18 | 0.050 |
Why?
| | Ear Diseases | 1 | 2004 | 17 | 0.050 |
Why?
| | Propylene Glycols | 1 | 2024 | 28 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2004 | 75 | 0.050 |
Why?
| | Aerospace Medicine | 1 | 2004 | 35 | 0.050 |
Why?
| | Sugars | 1 | 2024 | 42 | 0.050 |
Why?
| | Picornaviridae Infections | 1 | 2004 | 51 | 0.050 |
Why?
| | Saskatchewan | 1 | 2003 | 8 | 0.050 |
Why?
| | Decision Support Techniques | 1 | 2008 | 438 | 0.050 |
Why?
| | Shoulder | 1 | 2024 | 93 | 0.050 |
Why?
| | Nasal Mucosa | 1 | 2004 | 111 | 0.050 |
Why?
| | Fourier Analysis | 1 | 2003 | 40 | 0.050 |
Why?
| | Observation | 1 | 2003 | 56 | 0.050 |
Why?
| | Chicago | 1 | 2003 | 66 | 0.050 |
Why?
| | Probability | 2 | 2003 | 308 | 0.050 |
Why?
| | Food | 1 | 1984 | 161 | 0.050 |
Why?
| | Free Radical Scavengers | 4 | 2012 | 86 | 0.050 |
Why?
| | Wakefulness | 1 | 2004 | 170 | 0.050 |
Why?
| | Computing Methodologies | 1 | 2003 | 3 | 0.050 |
Why?
| | Maps as Topic | 1 | 2003 | 5 | 0.050 |
Why?
| | Phosphotyrosine | 2 | 2000 | 40 | 0.050 |
Why?
| | Coroners and Medical Examiners | 1 | 2022 | 8 | 0.050 |
Why?
| | Maternal-Fetal Exchange | 2 | 2015 | 170 | 0.050 |
Why?
| | Efficiency | 1 | 2003 | 101 | 0.050 |
Why?
| | Terminology as Topic | 1 | 1985 | 250 | 0.050 |
Why?
| | Washington | 1 | 2003 | 162 | 0.050 |
Why?
| | Geographic Information Systems | 1 | 2003 | 45 | 0.050 |
Why?
| | Genomics | 1 | 2008 | 831 | 0.050 |
Why?
| | Neoplasm Staging | 2 | 2021 | 1416 | 0.050 |
Why?
| | Income | 2 | 1994 | 198 | 0.050 |
Why?
| | Body Constitution | 1 | 2002 | 54 | 0.050 |
Why?
| | Steroids | 1 | 2003 | 165 | 0.050 |
Why?
| | Nitrosamines | 2 | 2012 | 9 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2004 | 242 | 0.050 |
Why?
| | Sleep Wake Disorders | 1 | 2006 | 315 | 0.050 |
Why?
| | Macrophages, Alveolar | 2 | 1997 | 373 | 0.050 |
Why?
| | Peer Group | 1 | 2004 | 251 | 0.050 |
Why?
| | Epidemiologic Measurements | 1 | 2001 | 1 | 0.050 |
Why?
| | Chi-Square Distribution | 2 | 2006 | 527 | 0.050 |
Why?
| | Joint Instability | 1 | 2024 | 171 | 0.040 |
Why?
| | Chelating Agents | 2 | 1999 | 73 | 0.040 |
Why?
| | Toxins, Biological | 1 | 2001 | 12 | 0.040 |
Why?
| | Invertebrates | 1 | 2001 | 24 | 0.040 |
Why?
| | Internet | 1 | 2006 | 698 | 0.040 |
Why?
| | Philadelphia | 2 | 1998 | 53 | 0.040 |
Why?
| | France | 1 | 2021 | 40 | 0.040 |
Why?
| | Schizophrenia | 1 | 2025 | 442 | 0.040 |
Why?
| | Vitamin A | 3 | 1987 | 56 | 0.040 |
Why?
| | Likelihood Functions | 1 | 2001 | 144 | 0.040 |
Why?
| | Patient Acceptance of Health Care | 1 | 1988 | 884 | 0.040 |
Why?
| | Sinusitis | 1 | 2004 | 239 | 0.040 |
Why?
| | Food Chain | 1 | 2001 | 46 | 0.040 |
Why?
| | Fishes | 1 | 2001 | 110 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2008 | 11365 | 0.040 |
Why?
| | Germany | 1 | 2021 | 139 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2023 | 418 | 0.040 |
Why?
| | Population Dynamics | 1 | 2001 | 156 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2002 | 773 | 0.040 |
Why?
| | Pilot Projects | 1 | 2006 | 1838 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2016 | 2017 | 0.040 |
Why?
| | Postmenopause | 1 | 2002 | 377 | 0.040 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2010 | 1413 | 0.040 |
Why?
| | Mathematics | 1 | 2000 | 103 | 0.040 |
Why?
| | Respiratory Hypersensitivity | 1 | 2000 | 69 | 0.040 |
Why?
| | Receptors, Progesterone | 1 | 2002 | 344 | 0.040 |
Why?
| | Stem Cells | 1 | 2004 | 619 | 0.040 |
Why?
| | Chromosome Deletion | 2 | 1997 | 124 | 0.040 |
Why?
| | Drug Interactions | 2 | 2003 | 406 | 0.040 |
Why?
| | Confidence Intervals | 3 | 2009 | 332 | 0.040 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 1999 | 44 | 0.040 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1999 | 46 | 0.040 |
Why?
| | Smoking Water Pipes | 1 | 2019 | 9 | 0.040 |
Why?
| | Health Status Indicators | 2 | 2000 | 161 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2002 | 425 | 0.040 |
Why?
| | Bibliometrics | 1 | 1999 | 59 | 0.040 |
Why?
| | Culture Media | 1 | 1999 | 165 | 0.040 |
Why?
| | Religious Personnel | 1 | 2018 | 1 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 1999 | 148 | 0.040 |
Why?
| | Fossil Fuels | 2 | 2001 | 10 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2000 | 302 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 1998 | 639 | 0.040 |
Why?
| | Heart Rate | 1 | 2002 | 844 | 0.040 |
Why?
| | Activities of Daily Living | 2 | 1993 | 429 | 0.040 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2000 | 233 | 0.040 |
Why?
| | Maternal Age | 1 | 1998 | 131 | 0.040 |
Why?
| | Acculturation | 1 | 2018 | 53 | 0.030 |
Why?
| | Copper | 1 | 1998 | 115 | 0.030 |
Why?
| | Anthropometry | 1 | 2018 | 208 | 0.030 |
Why?
| | DNA Adducts | 1 | 1997 | 16 | 0.030 |
Why?
| | Benzo(a)pyrene | 1 | 1997 | 8 | 0.030 |
Why?
| | Mice | 4 | 2008 | 18378 | 0.030 |
Why?
| | Lactation | 1 | 1998 | 192 | 0.030 |
Why?
| | Arizona | 2 | 2006 | 81 | 0.030 |
Why?
| | Stakeholder Participation | 1 | 2018 | 81 | 0.030 |
Why?
| | Clinical Competence | 1 | 2025 | 1235 | 0.030 |
Why?
| | Interleukin-6 | 2 | 1998 | 781 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 101 | 0.030 |
Why?
| | HIV Seronegativity | 1 | 1996 | 30 | 0.030 |
Why?
| | Injury Severity Score | 1 | 2019 | 575 | 0.030 |
Why?
| | Weight Loss | 1 | 2022 | 811 | 0.030 |
Why?
| | Marriage | 3 | 1987 | 122 | 0.030 |
Why?
| | Multilevel Analysis | 1 | 2016 | 36 | 0.030 |
Why?
| | Silicon Dioxide | 1 | 1997 | 118 | 0.030 |
Why?
| | Social Support | 2 | 1993 | 635 | 0.030 |
Why?
| | Mice, Inbred CBA | 1 | 1996 | 58 | 0.030 |
Why?
| | Chemical Industry | 1 | 1996 | 9 | 0.030 |
Why?
| | Phospholipases A2 | 1 | 1996 | 81 | 0.030 |
Why?
| | New Zealand | 1 | 2016 | 57 | 0.030 |
Why?
| | Body Weight | 1 | 2021 | 1003 | 0.030 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 1996 | 36 | 0.030 |
Why?
| | Needs Assessment | 1 | 1999 | 392 | 0.030 |
Why?
| | Head and Neck Neoplasms | 1 | 2001 | 562 | 0.030 |
Why?
| | Acetylcysteine | 2 | 2012 | 146 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 1998 | 389 | 0.030 |
Why?
| | South Africa | 1 | 2016 | 208 | 0.030 |
Why?
| | Government Agencies | 1 | 1995 | 15 | 0.030 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2016 | 99 | 0.030 |
Why?
| | Eicosanoids | 1 | 1996 | 59 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2006 | 4522 | 0.030 |
Why?
| | Africa, Central | 1 | 2015 | 6 | 0.030 |
Why?
| | Genotype | 2 | 2014 | 1877 | 0.030 |
Why?
| | Indians, Central American | 1 | 2015 | 6 | 0.030 |
Why?
| | Asia, Southeastern | 1 | 2015 | 12 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 1999 | 839 | 0.030 |
Why?
| | Central America | 1 | 2015 | 24 | 0.030 |
Why?
| | Indians, South American | 1 | 2015 | 23 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 2 | 1998 | 2531 | 0.030 |
Why?
| | Microscopy, Electron | 1 | 1996 | 415 | 0.030 |
Why?
| | Educational Status | 2 | 1996 | 464 | 0.030 |
Why?
| | Demography | 2 | 2000 | 297 | 0.030 |
Why?
| | Neoplasms, Experimental | 1 | 1996 | 174 | 0.030 |
Why?
| | Carrier Proteins | 1 | 1999 | 752 | 0.030 |
Why?
| | Homosexuality, Male | 1 | 1996 | 207 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 1997 | 341 | 0.030 |
Why?
| | Random Allocation | 1 | 1995 | 370 | 0.030 |
Why?
| | Carbohydrate Sequence | 1 | 1994 | 29 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1671 | 0.030 |
Why?
| | Animals, Newborn | 1 | 1997 | 882 | 0.030 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2015 | 116 | 0.030 |
Why?
| | Breast Feeding | 1 | 1998 | 444 | 0.030 |
Why?
| | Cytokines | 2 | 2003 | 2097 | 0.030 |
Why?
| | Population Density | 1 | 1994 | 99 | 0.030 |
Why?
| | Linkage Disequilibrium | 1 | 2014 | 254 | 0.030 |
Why?
| | Occupations | 2 | 2000 | 51 | 0.030 |
Why?
| | Hydrocarbons | 1 | 1993 | 31 | 0.030 |
Why?
| | Mental Competency | 1 | 1993 | 25 | 0.030 |
Why?
| | Patient Care Team | 1 | 1999 | 690 | 0.020 |
Why?
| | Ecosystem | 1 | 2018 | 583 | 0.020 |
Why?
| | Fatty Acids | 1 | 1996 | 452 | 0.020 |
Why?
| | Heart Failure | 1 | 2006 | 2131 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2015 | 282 | 0.020 |
Why?
| | Membrane Proteins | 1 | 1999 | 1171 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1369 | 0.020 |
Why?
| | Family Health | 1 | 1994 | 197 | 0.020 |
Why?
| | Ecology | 1 | 1994 | 119 | 0.020 |
Why?
| | Vital Statistics | 1 | 1992 | 5 | 0.020 |
Why?
| | Transportation of Patients | 1 | 1993 | 67 | 0.020 |
Why?
| | Cadmium | 1 | 2012 | 68 | 0.020 |
Why?
| | Molecular Sequence Data | 2 | 1994 | 2942 | 0.020 |
Why?
| | Biopsy | 1 | 2015 | 1083 | 0.020 |
Why?
| | Electric Impedance | 1 | 2012 | 112 | 0.020 |
Why?
| | Permeability | 1 | 2012 | 169 | 0.020 |
Why?
| | Genes, p53 | 1 | 1992 | 68 | 0.020 |
Why?
| | Genes, ras | 1 | 1992 | 94 | 0.020 |
Why?
| | Physical Fitness | 1 | 1993 | 207 | 0.020 |
Why?
| | Africa | 1 | 2012 | 114 | 0.020 |
Why?
| | Drug Evaluation | 1 | 2011 | 79 | 0.020 |
Why?
| | Alleles | 1 | 2014 | 893 | 0.020 |
Why?
| | Sick Leave | 1 | 2011 | 15 | 0.020 |
Why?
| | Otitis Media | 1 | 1994 | 176 | 0.020 |
Why?
| | Safety | 1 | 1993 | 357 | 0.020 |
Why?
| | Quality of Life | 1 | 2003 | 3080 | 0.020 |
Why?
| | Recreation | 1 | 2011 | 26 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4658 | 0.020 |
Why?
| | Survivors | 2 | 2004 | 502 | 0.020 |
Why?
| | HIV-1 | 1 | 2016 | 892 | 0.020 |
Why?
| | Macrophages | 1 | 1998 | 1506 | 0.020 |
Why?
| | Dichlorodiphenyldichloroethane | 1 | 2009 | 1 | 0.020 |
Why?
| | RNA, Messenger | 4 | 1998 | 2852 | 0.020 |
Why?
| | Disease Progression | 1 | 1998 | 2856 | 0.020 |
Why?
| | Coffee | 1 | 2009 | 14 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2009 | 61 | 0.020 |
Why?
| | Mass Media | 1 | 2010 | 41 | 0.020 |
Why?
| | Health Services | 1 | 1990 | 116 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2009 | 122 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2014 | 445 | 0.020 |
Why?
| | Reactive Oxygen Species | 1 | 2012 | 642 | 0.020 |
Why?
| | Thorium | 1 | 1989 | 2 | 0.020 |
Why?
| | Ether | 1 | 2009 | 8 | 0.020 |
Why?
| | Radium | 1 | 1989 | 4 | 0.020 |
Why?
| | Metallurgy | 1 | 1989 | 9 | 0.020 |
Why?
| | Methylene Chloride | 1 | 2009 | 5 | 0.020 |
Why?
| | Colorectal Neoplasms | 2 | 1996 | 833 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 1990 | 153 | 0.020 |
Why?
| | Culture | 1 | 2010 | 130 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 1993 | 1099 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 1998 | 2621 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 1992 | 524 | 0.020 |
Why?
| | Taiwan | 1 | 2008 | 46 | 0.020 |
Why?
| | Death Certificates | 1 | 1988 | 30 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 593 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2010 | 241 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2936 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1996 | 2020 | 0.020 |
Why?
| | Industrial Waste | 1 | 2008 | 6 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 1994 | 590 | 0.020 |
Why?
| | Liver | 1 | 1997 | 1864 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 1990 | 259 | 0.020 |
Why?
| | Ovalbumin | 1 | 2008 | 197 | 0.020 |
Why?
| | Welding | 1 | 1987 | 2 | 0.020 |
Why?
| | Government Programs | 1 | 2008 | 27 | 0.020 |
Why?
| | Paint | 1 | 1987 | 9 | 0.020 |
Why?
| | Texas | 1 | 1988 | 273 | 0.020 |
Why?
| | Forced Expiratory Flow Rates | 1 | 1987 | 10 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2009 | 230 | 0.020 |
Why?
| | Peak Expiratory Flow Rate | 1 | 1987 | 25 | 0.020 |
Why?
| | Schools | 1 | 2011 | 459 | 0.020 |
Why?
| | Conservation of Energy Resources | 1 | 2007 | 3 | 0.020 |
Why?
| | Behavior Therapy | 1 | 2010 | 283 | 0.020 |
Why?
| | Physical Examination | 1 | 1988 | 245 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2014 | 2177 | 0.020 |
Why?
| | Calcium | 1 | 2012 | 1183 | 0.020 |
Why?
| | Radiation Monitoring | 1 | 1986 | 15 | 0.020 |
Why?
| | Massachusetts | 1 | 2006 | 179 | 0.020 |
Why?
| | Attitude | 1 | 1988 | 258 | 0.020 |
Why?
| | Air Conditioning | 1 | 2006 | 6 | 0.020 |
Why?
| | HIV | 1 | 2007 | 249 | 0.010 |
Why?
| | Medical History Taking | 1 | 1986 | 118 | 0.010 |
Why?
| | Arousal | 1 | 2006 | 158 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2012 | 1370 | 0.010 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2007 | 278 | 0.010 |
Why?
| | Rural Population | 2 | 1987 | 617 | 0.010 |
Why?
| | Physicians | 1 | 1994 | 940 | 0.010 |
Why?
| | Electronic Health Records | 1 | 2013 | 1163 | 0.010 |
Why?
| | Statistics as Topic | 1 | 1986 | 298 | 0.010 |
Why?
| | beta Carotene | 1 | 1984 | 20 | 0.010 |
Why?
| | Carotenoids | 1 | 1984 | 42 | 0.010 |
Why?
| | Dementia | 1 | 1988 | 292 | 0.010 |
Why?
| | Nitrogen Oxides | 1 | 2004 | 54 | 0.010 |
Why?
| | X-Rays | 1 | 2003 | 31 | 0.010 |
Why?
| | Pneumoconiosis | 1 | 1984 | 20 | 0.010 |
Why?
| | Heart Conduction System | 1 | 2004 | 92 | 0.010 |
Why?
| | Biophysical Phenomena | 1 | 2003 | 69 | 0.010 |
Why?
| | Population | 1 | 2003 | 32 | 0.010 |
Why?
| | Gamma Rays | 1 | 2003 | 57 | 0.010 |
Why?
| | Biophysics | 1 | 2003 | 76 | 0.010 |
Why?
| | Oxyhemoglobins | 1 | 2003 | 24 | 0.010 |
Why?
| | Cell Line | 2 | 1998 | 2897 | 0.010 |
Why?
| | Databases, Factual | 1 | 2008 | 1465 | 0.010 |
Why?
| | Mothers | 1 | 2009 | 783 | 0.010 |
Why?
| | Training Support | 1 | 2002 | 36 | 0.010 |
Why?
| | Blood Pressure | 1 | 2009 | 1755 | 0.010 |
Why?
| | Receptors, Phospholipase A2 | 1 | 2001 | 1 | 0.010 |
Why?
| | Pharyngeal Neoplasms | 1 | 2001 | 5 | 0.010 |
Why?
| | Interleukin-3 | 1 | 2001 | 24 | 0.010 |
Why?
| | Annexin A5 | 1 | 2001 | 25 | 0.010 |
Why?
| | Polymerase Chain Reaction | 2 | 1997 | 1062 | 0.010 |
Why?
| | Vital Capacity | 1 | 2003 | 311 | 0.010 |
Why?
| | Oxidants, Photochemical | 1 | 2001 | 8 | 0.010 |
Why?
| | Food Contamination | 1 | 2001 | 54 | 0.010 |
Why?
| | Lysophospholipids | 1 | 2001 | 75 | 0.010 |
Why?
| | Disease Transmission, Infectious | 1 | 2001 | 70 | 0.010 |
Why?
| | Pancreatic Neoplasms | 1 | 2009 | 924 | 0.010 |
Why?
| | Mouth Neoplasms | 1 | 2001 | 89 | 0.010 |
Why?
| | Isoenzymes | 1 | 2001 | 299 | 0.010 |
Why?
| | Mutation | 1 | 1992 | 4053 | 0.010 |
Why?
| | Parents | 1 | 1989 | 1456 | 0.010 |
Why?
| | Immunoenzyme Techniques | 1 | 2000 | 206 | 0.010 |
Why?
| | Fungi | 1 | 2001 | 156 | 0.010 |
Why?
| | Agriculture | 1 | 2000 | 104 | 0.010 |
Why?
| | Melanoma | 2 | 1986 | 807 | 0.010 |
Why?
| | Extracellular Matrix | 1 | 2003 | 558 | 0.010 |
Why?
| | Reference Values | 1 | 2000 | 811 | 0.010 |
Why?
| | Ceruloplasmin | 1 | 1998 | 10 | 0.010 |
Why?
| | Fuel Oils | 1 | 1998 | 2 | 0.010 |
Why?
| | Boston | 1 | 1978 | 92 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 2001 | 453 | 0.010 |
Why?
| | Histocytochemistry | 1 | 1998 | 80 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2000 | 790 | 0.010 |
Why?
| | Utah | 1 | 1998 | 82 | 0.010 |
Why?
| | Receptors, Transferrin | 1 | 1998 | 28 | 0.010 |
Why?
| | Cell Survival | 1 | 2001 | 1136 | 0.010 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1998 | 143 | 0.010 |
Why?
| | Thiourea | 1 | 1997 | 41 | 0.010 |
Why?
| | Autoradiography | 1 | 1997 | 65 | 0.010 |
Why?
| | Software | 1 | 2003 | 687 | 0.010 |
Why?
| | Blotting, Western | 1 | 2000 | 1223 | 0.010 |
Why?
| | Respiratory Mucosa | 1 | 2000 | 325 | 0.010 |
Why?
| | Intubation, Intratracheal | 1 | 2000 | 313 | 0.010 |
Why?
| | Interferons | 1 | 1998 | 195 | 0.010 |
Why?
| | Sputum | 1 | 1978 | 313 | 0.010 |
Why?
| | Microsatellite Repeats | 1 | 1997 | 160 | 0.010 |
Why?
| | Heterozygote | 1 | 1997 | 311 | 0.010 |
Why?
| | Interleukin-8 | 1 | 1997 | 270 | 0.010 |
Why?
| | Epithelium | 1 | 1997 | 314 | 0.010 |
Why?
| | Comorbidity | 1 | 2001 | 1678 | 0.010 |
Why?
| | Age of Onset | 1 | 1998 | 548 | 0.010 |
Why?
| | Heart Defects, Congenital | 1 | 2004 | 887 | 0.010 |
Why?
| | Transfection | 1 | 1998 | 949 | 0.010 |
Why?
| | Protein Binding | 1 | 2001 | 2261 | 0.010 |
Why?
| | Skin Neoplasms | 1 | 1982 | 869 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2001 | 1511 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 1997 | 626 | 0.010 |
Why?
| | Pacific Islands | 1 | 1994 | 3 | 0.010 |
Why?
| | West Virginia | 1 | 1993 | 9 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 1998 | 1263 | 0.010 |
Why?
| | Apoptosis | 1 | 2001 | 2519 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1997 | 1226 | 0.010 |
Why?
| | Platelet Activating Factor | 1 | 1992 | 48 | 0.010 |
Why?
| | Primary Prevention | 1 | 1994 | 202 | 0.010 |
Why?
| | Prostaglandins | 1 | 1992 | 97 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 1994 | 560 | 0.010 |
Why?
| | Codon | 1 | 1992 | 92 | 0.010 |
Why?
| | DNA, Neoplasm | 1 | 1992 | 162 | 0.010 |
Why?
| | DNA | 1 | 1998 | 1457 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 1992 | 1064 | 0.010 |
Why?
| | Base Sequence | 1 | 1992 | 2199 | 0.000 |
Why?
| | Cognition | 1 | 1996 | 1261 | 0.000 |
Why?
| | Carcinoma, Bronchogenic | 1 | 1986 | 20 | 0.000 |
Why?
| | Eye Neoplasms | 1 | 1986 | 29 | 0.000 |
Why?
| | Carcinoma, Small Cell | 1 | 1987 | 172 | 0.000 |
Why?
| | Feasibility Studies | 1 | 1990 | 1051 | 0.000 |
Why?
| | Retinoblastoma | 1 | 1986 | 49 | 0.000 |
Why?
| | Lymphoma | 1 | 1986 | 228 | 0.000 |
Why?
| | Self Disclosure | 1 | 1984 | 66 | 0.000 |
Why?
| | Leukemia | 1 | 1986 | 245 | 0.000 |
Why?
| | Neck | 1 | 1982 | 107 | 0.000 |
Why?
| | Head | 1 | 1982 | 122 | 0.000 |
Why?
|
|
Samet's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|